Discussion on security application of antiangiogenic agents from upper gastrointestinal bleeding in a patient with ulcer-gastric carcinoma
YANG Xiao-rui
LIANG Ming-jie
WANG Wei-lan
Abstract：One 56-year-old male patient was hospitalized for gastric adenocarcinoma with liver and lymph node metastases for more than 1.5 years. The patient had received 16 periods of chemotherapy, observed as progressive disease (PD). After administration of apatinib (850 mg, qd) for a month, the patient developed stable disease (SD). For the current chemotherapy, apart from apatinib, bevacizumab was peritoneal perfused at the 1st and 7th day to control malignant hydroperitoneum. However, on the 8th day, upper gastrointestinal hemorrhage appeared and the apatinib or bevacizumab treatment was stopped. Patient was accordingly treated with acid suppression, as well as emergent intervention of hemostasis and transfusion. Subsequently, clinical symptoms were markedly improved. Clinical pharmacists discussed the bleeding tendency and prevention measures of antiangiogenic agents on ulcer-gastric carcinoma patients according to the current report and references. It was suggested that: bleeding tendency merit close attention when using antiangiogenic agents; patients with high bleeding tendency should be prudent to use antiangiogenic agents, especially for 2 or more kinds of antiangiogenic agents.
Keywords：Ulcer-gastric carcinomaUpper gastrointestinal hemorrhageAntiangiogenic agentsSecurity application
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 280-283 )